Ask AI
ProCE Banner Activity

TROPION-Breast01: Efficacy and Safety From Phase III Trial of Datopotamab Deruxtecan vs Chemotherapy for Patients With Previously Treated HR+/HER2- Advanced Breast Cancer

Conference Coverage
Slideset

Analysis of the phase III TROPION-Breast01 trial of datopotamab deruxtecan vs chemotherapy in previously treated HR+/HER2- advanced breast cancer showed a PFS benefit with datopotamab deruxtecan regardless of prior duration of CDK4/6 inhibitor therapy or baseline brain metastases, tolerable safety, and improved quality of life vs chemotherapy.

Released: December 11, 2023

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme, LLC

Seagen Inc.